SVB Securities analyst Daina Graybosch maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report) on November 7 and set a price target of $5.00. The company’s shares closed yesterday at $3.58.
Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, Nektar Therapeutics, and Affimed. According to TipRanks, Graybosch has an average return of -19.2% and a 30.36% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $5.23 average price target, implying a 46.09% upside from current levels. In a report released on November 3, Mizuho Securities also maintained a Hold rating on the stock with a $6.00 price target.
Based on Nektar Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $23.63 million and a GAAP net loss of $59.05 million. In comparison, last year the company earned a revenue of $24.92 million and had a GAAP net loss of $129.71 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR:
- Nektar Therapeutics Reports Third Quarter 2022 Financial Results
- Nektar, PureTech terminate business combination discussions
- PureTech sinks 18% after disclosing merger talks with Nektar
- PureTech Health confirms talks with Nektar regarding potential combination
- PureTech Health (NASDAQ:PRTC) Considering Merger with Nektar